Where is CSG Bio located?

CSG Bio is headquartered in Scottsdale, United States.

Where does CSG Bio rank among its competitors?

CSG Bio ranks 9th amongst 11 active competitors, of which 3 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sarcio, which secured $785K in Jul, 2023.

Who are the top competitors of CSG Bio?

CSG Bio's top competitors include Cimeio Therapeutics, Bioloomics and Stem Cells Baby. Among them, Sarcio secured the most recent funding round in July, 2023.

CSG Bio - 2026 Company Profile & Competitors

Company Details

Provider of stem cell collection and long term storage services. Biological samples are processed and preserved using standardized laboratory protocols. These services facilitate the maintenance of cellular material for potential future medical applications.

Key Metrics

Founded Year

2000

Location

Scottsdale, United States

Stage

Unfunded

Ranked

9^th among 11 active competitors

Similar Companies

Cimeio Therapeutics & 10 more

View CSG Bio's full profile

CSG Bio has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CSG Bio include Cimeio Therapeutics, Bioloomics and Stem Cells Baby. Here is the list of Top 10 competitors of CSG Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cimeio Therapeutics 2020, Basel (Switzerland), Series A	Provider of hematopoietic stem cell transplant and adoptive cell therapy services	$50M	Versant Ventures, BaseLaunch	33/100
2nd	Bioloomics 2018, Boulder (United States), Seed	Limited information available	$9.95M	Innovation Endeavors, Hummingbird Ventures ... & 6 others	32/100
3rd	Stem Cells Baby 2000, West Drayton (United Kingdom), Early Stage	Operator of a stem cell storage bank for future use	$600K	-	23/100
4th	Sarcio 2017, Minneapolis (United States), Seed	Developer of an allogenic, iPSC-derived cartilage cell therapy for osteoarthritis. This therapy aims to restore hyaline cartilage and reduce inflammation, delaying or preventing the need for joint replacement surgery. The treatment is designed to be off-the-shelf and injectable, providing a less invasive alternative to traditional methods. The company's approach focuses on reaching patients early to improve joint function and alleviate pain. The technology utilizes high-quality hyaline cartilage cells generated through a proprietary method to achieve cartilage restoration, regeneration, and repair.	$785K	-	20/100
5th	Store a Cell 2012, Mexico City (Mexico), Funding Raised	Provider of mesenchymal stem cells storage services	-	-	19/100
6th	Korean Skin Stem Cell Center Switzerland, Unfunded	Provider of stem cell therapies for tissue regeneration and aesthetic applications	-	-	16/100
7th	ViviCells International 2018, Evanston (United States), Unfunded	Healthcare company focused on the collection, storage, and processing of stem cells	-	-	16/100
8th	Integrated-Health-Systems Unfunded	Provider of regenerative medicine therapies including gene, stem cell, and exosomes	-	-	16/100
9th	CSG Bio 2000, Scottsdale (United States), Unfunded	Provider of stem cell collection and long term storage services	-	-	16/100
10th	Regenerative Care Network 2017, Austin (United States), Deadpooled	Provides access to regenerative cell therapy and allows texas doctors to administer stem cell therapy legally	-	-	16/100